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Abstract
Background: Women have been able to delay childbearing since effective contraception became available in the 1960s.
However, fertility decreases with increasing maternal age. A slow but steady decrease in fertility is observed in women aged
between 30 and 35 years, which is followed by an accelerated decline among women aged over 35 years. A combination of
delayed childbearing and reduced fecundity with increasing age has resulted in an increased number and proportion of women
of greater than or equal to 35 years of age seeking assisted reproductive technology (ART) treatment.
Methods: Literature searches supplemented with the authors' knowledge.
Results: Despite major advances in medical technology, there is currently no ART treatment strategy that can fully compensate
for the natural decline in fertility with increasing female age. Although chronological age is the most important predictor of
ovarian response to follicle-stimulating hormone, the rate of reproductive ageing and ovarian sensitivity to gonadotrophins
varies considerably among individuals. Both environmental and genetic factors contribute to depletion of the ovarian oocyte
pool and reduction in oocyte quality. Thus, biological and chronological ovarian age are not always equivalent. Furthermore,
biological age is more important than chronological age in predicting the outcome of ART. As older patients present increasingly
for ART treatment, it will become more important to critically assess prognosis, counsel appropriately and optimize treatment
strategies. Several genetic markers and biomarkers (such as anti-Müllerian hormone and the antral follicle count) are emerging
that can identify women with accelerated biological ovarian ageing. Potential strategies for improving ovarian response include
the use of luteinizing hormone (LH) and growth hormone (GH). When endogenous LH levels are heavily suppressed by
gonadotrophin-releasing hormone analogues, LH supplementation may help to optimize treatment outcomes for women with
biologically older ovaries. Exogenous GH may improve oocyte development and counteract the age-related decline of oocyte
quality. The effects of GH may be mediated by insulin-like growth factor-I, which works synergistically with follicle-stimulating
hormone on granulosa and theca cells.
Conclusion:  Patients with biologically older ovaries may benefit from a tailored approach based on individual patient
characteristics. Among the most promising adjuvant therapies for improving ART outcomes in women of advanced reproductive
age are the administration of exogenous LH or GH.
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Background
Over recent years, the average age of patients seeking infer-
tility treatment has increased [1]. Since the development
of effective contraception in the 1960s, women have been
able to delay childbearing [2,3], and the average maternal
age increased by approximately 5 years between the peri-
ods 1965-1969 and 1995-1999 [3]. The tendency towards
deferred childbirth has also risen steadily since assisted
reproductive technology (ART) treatments for infertility
became available in 1980 [4,5] (Fig. 1).
After approximately 30 years of age, fertility decreases
with increasing age, with a slow but steady decline in fer-
tility in women aged between 30 and 35 years, which is
followed by an accelerated decline [6,7]. Data from the
16th to the early 19th century show that women who mar-
ried late were more likely to die childless; women who
married when more than 35 years of age had twice the
chance of dying childless compared with those who mar-
ried when aged 30-34 years [8]. Thus, delayed childbear-
ing reduces the chance of achieving a spontaneous
pregnancy [6].
A combination of delayed childbearing and reduced nat-
ural fecundity with increasing age has resulted in a steady
increase in the number and proportion of women aged
≥35 years who are seeking ART treatment [9]. Unfortu-
nately, the outcomes of treatment with ART are also
adversely affected by advanced patient age, and it is
becoming increasingly important to optimize treatment
outcomes for these older patients [10].
Although chronological age is the most important predic-
tor of ovarian response to follicle-stimulating hormone
(FSH), the rate of reproductive ageing varies considerably
among individuals. Both environmental and genetic fac-
tors contribute to biological ovarian ageing. Thus, chron-
ological and biological age are not always equivalent. We
review here the principal developmental and endocrine
mechanisms of ovarian ageing that underlie the variability
between chronological and biological age. We will also
discuss the effect of biological ovarian ageing on ART
treatment outcomes and consider potential treatment
strategies for those of advanced biological reproductive
age.
Methods
Electronic literature searches were performed via PubMed
using combinations of the following keywords to identify
relevant articles: 'AFC', 'age', 'AMH', 'ART', 'assisted repro-
duction', 'environmental', 'folliculogenesis', 'FSH',
'genetic', gonadotrophin', 'GH', 'infertility', 'LH', 'oogene-
sis' and 'ovarian'. All types of articles published in the Eng-
lish language were permitted and were unlimited by date
of publication. The resulting publications were examined
for relevance to the scope of the review (namely genetic
and environmental factors that may influence ovarian
ageing, the effect of biological ovarian ageing on ART out-
comes, and potential treatment strategies for women of
advanced biological reproductive age) and supplemented
with other key publications that were known to the
authors.
Ovarian function: folliculogenesis and oogenesis
The different stages of folliculogenesis are illustrated in
Fig. 2 [11]. At birth, the ovaries contain a stock of approx-
imately 1-2 million oocytes that are arrested at the first
meiotic prophase [12]. Oocytes at the first meiotic
prophase undergo atresia or resume meiosis after activa-
tion by an ovulation-inducing luteinizing hormone (LH)
surge to form the haploid gamete for fertilization. In fact,
almost all (99.9%) of the oocytes present at birth undergo
atresia via apoptotic mechanisms [13]. Indeed, the total
number of viable oocytes present in the ovaries at the
onset of puberty is a small fraction of that present at birth.
The life-cycle of preovulatory follicles can be broken
down into three successive phases: initiation, which
occurs from birth to old age and is independent of gona-
dotrophic support; FSH-dependent progression, which
requires tonic stimulation by FSH; and LH-responsive
maturation, which occurs when FSH-induced genes fall
under LH control, leading to oestrogen secretion and ovu-
lation [14,15]. These processes ensure that the 'right'
number of follicles are available at the 'right' stage of
development, at the 'right' time in the menstrual cycle.
Mean age at first childbirth in European women between  1980 and 2005 Figure 1
Mean age at first childbirth in European women 
between 1980 and 2005. Reproduced with permission 
from T. Sobotka (pers. commun.).
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Early stages
Early stages of follicular growth are characterized by
oocyte enlargement, granulosa cell proliferation (forming
multiple layers around the oocyte) and development of
the theca interna. From early infancy onwards, the pro-
portion of the total number of healthy primordial follicles
that proceeds to further development remains constant
throughout a woman's reproductive life. Therefore, as the
number of oocytes present in the ovaries decreases, the
absolute number of developing follicles progressively
declines with age [16].
The mechanisms responsible for initiating follicular
growth are independent of gonadotrophins and may orig-
inate in the oocyte itself [17]. When a primordial follicle
grows, the oocyte increases in size and the flattened cells
surrounding it become cuboidal and proliferate to form
the granulosa cell layer; the structure is then called a 'pri-
mary' follicle. All primary follicles that develop before
puberty are destined to undergo atresia because the gona-
dotrophin support needed to promote full preovulatory
growth is absent until shortly after this event [18]. Granu-
losa cells in healthy primary follicles continue to divide to
produce two or more layers while the zona pellucida
forms around the enlarging oocyte. Outside the basement
membrane, a layer of cells differentiates from the stroma
and becomes the theca interna. The structure is now called
a preantral follicle.
Intermediate stages
When approximately three layers of granulosa cells have
formed in preantral follicles, fluid-filled spaces appear
between the granulosa cells and gradually become conflu-
ent to form a single large antrum. Antrum formation is
gonadotrophin-dependent. In humans, this growth stage
lasts until follicles are approximately 2-4 mm in diameter.
Healthy antral follicles are on the brink of entering the ter-
minal stages of preovulatory development. However, to
do so, they require appropriate, cyclical gonadotrophin
stimulation. Thus, all antral follicles that develop before
puberty will become atretic.
Ovulation
Usually one preovulatory follicle develops during each
menstrual cycle, increasing in diameter from approxi-
mately 5 mm at the beginning of the cycle to more than
Life history of ovarian follicles endowment and maintenance, initial recruitment, maturation, atresia or cyclic recruitment, ovu- lation, and exhaustion Figure 2
Life history of ovarian follicles endowment and maintenance, initial recruitment, maturation, atresia or cyclic 
recruitment, ovulation, and exhaustion. Reproduced with permission from McGee and Hsueh. Initial and cyclic recruit-
ment of ovarian follicles. Endocr Rev 2000, 21:200-214. © 2000. The Endocrine Society.
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20 mm at ovulation 2 weeks later. During its last 6 days or
so of development, a follicle increasingly secretes oestro-
gen and inhibin (INH), the classic biomarkers of preovu-
latory follicular development. These hormones lead to
discharge of the mid-cycle LH surge from the pituitary
gland, which in turn triggers resumption of oocyte meiotic
maturation and ovulation.
The mechanisms of ovarian ageing
Follicular loss and the menopause
As a woman ages, her fecundity declines because of the
loss of follicles from the ovary [19] and an associated
reduction in oocyte quality [20]. The reduction in oocyte
quality is in line with the increased incidence of miscar-
riages and chromosomal aberrations that occur after the
age of 35 years [21]. The number of follicles in the human
ovary declines at a rate that is bi-exponential. The rate of
follicle loss more than doubles when the numbers fall
below the critical level of 25,000; which occurs at approx-
imately 37.5 years of age [22].
It has been suggested that a threshold number of follicles
is required to maintain a regular menstrual cycle [23]. The
peri-menopausal period is characterized by increasing
irregularity in cycle length. The transition from peri-men-
opause to menopause is complete when approximately
1000 follicles remain in the ovaries; this occurs at an aver-
age age of 51 years. The time taken to reach this point
from the critical threshold of 25,000 follicles seems to be
fairly constant, at approximately 13 years [24].
Several years before menstrual cycles cease, initiation of
follicular growth begins to accelerate, speeding up the loss
of the residual follicular stock [25]; this occurs at approx-
imately 35 years of age. This effect is associated with a
gradual increase in circulating levels of FSH.
The central role of FSH in termination of folliculogenesis
FSH orchestrates the termination of folliculogenesis in
human ovaries. The increase in circulating plasma FSH
levels appears to be due mainly to reduced secretion of
follicular growth and differentiation factors related to
transforming growth factor-b that negatively affect the
release of FSH from the pituitary gland.
INH and anti-Müllerian hormone (AMH) are produced
by immature ovarian follicles and help to regulate secre-
tion of FSH by the pituitary gland [26,27]. As the number
of immature follicles declines with age, negative feedback
control on FSH secretion is relaxed, and basal circulating
levels of FSH rise. High levels of FSH promote inappropri-
ate maturation of the granulosa cells of the residual prean-
tral (INH B-secreting) follicles containing ova that have
not completed their gonadotrophin-independent growth
phase. These follicles eventually become atretic, presuma-
bly because of the asynchronous maturation of their ger-
minal and somatic components. The process is amplified
as FSH levels continue to rise, until oestradiol and INH A
levels also fall in the late peri-menopause, and menstrual
cycles cease. The high FSH levels are also believed to
underpin the gradual shortening of the follicular phase of
the menstrual cycle with age, and the increased incidence
of dizygotic twins [28].
Variability in reproductive ageing
Variability in ovarian ageing
The size of the initial oocyte stock, the proportion that
undergoes atresia and the rate of initiation of growth of
follicles are genetically determined variables [16,29].
Thus, the age at which the menopause occurs varies
among individuals, and is determined mainly by genetic
factors.
The peri-menopausal period, from the onset of cycle irreg-
ularity to menopause, is reported to be approximately 6
years, regardless of the age at menopause [30]. Similarly,
the onset of subfertility for each individual woman is
believed to begin at a relatively fixed interval prior to the
menopause. This is corroborated by data from ART stud-
ies: women who respond poorly to ovarian stimulation
tend to reach the menopause earlier [31-34]. Women who
respond poorly to ovarian stimulation may be at a stage
between the accelerated decline and complete loss of fer-
tility.
Epidemiological studies show that 10% of women in the
general population are menopausal by the age of 45 years
[35,36]. Assuming a time interval of 13 years between the
accelerated decline of ovarian follicles and complete loss
of fertility, a woman who reaches the menopause at the
age of 45 years may have begun a decline in follicle quan-
tity and quality at approximately 32 years of age
(although the maintenance of regular menstrual cycles
would make her unaware of this possibility). Therefore,
10% of women may be at risk of unexplained reduced
fecundity during their third decade. These women may
have a poor response to ovarian stimulation, and could be
described as having early 'biological ovarian ageing'.
Variability in ageing reflected by levels of gonadotrophins
FSH levels begin to increase long before the onset of men-
strual cycle irregularity, and continue to rise thereafter
[37,38]. Levels of both FSH and LH rise steadily during the
period of follicle depletion during the peri-menopausal
period, but the detailed dynamics involved are incom-
pletely understood. The serum LH concentration usually
starts to increase after the rise in FSH concentration, but in
some cases this effect is not observed at all [39-41].
Ferrell et al. conducted a 5-year prospective study in order
to investigate age-related changes in LH and FSH, in a
group of 156 women within an age range of 25-58 yearsReproductive Biology and Endocrinology 2009, 7:101 http://www.rbej.com/content/7/1/101
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at the beginning of the study [42]. The participants pro-
vided daily urine samples for 6 months per year in five
consecutive years. These samples were analysed for aggre-
gate distributions with age, individual trajectories with
age, and variance in age-specific estimates within and
between women.
The study confirmed that both FSH and LH levels increase
with age, but the timing and magnitude of these changes
were different for each hormone and varied among indi-
viduals. Both FSH and LH increased dramatically during
the later peri-menopausal stages. FSH levels increased
from normal to high within a relatively short time frame
in the peri-menopausal years (<5 years). Although the
most rapid increase in aggregate and individual FSH levels
occurred after the age of 45, an increasing level of FSH was
observed even in young women. However, any aggregate
estimates of FSH or LH levels may be misleading as they
represent a mixture of different trends seen in individuals,
who have widely varying levels at different ages, and the
rate of increase also differs among individuals. Figure 3
illustrates that the serum FSH rise started at different FSH
concentrations for each woman. Thus, the findings of Fer-
rell et al. [42] illustrate the variable rate of ovarian ageing
among individuals reflected in gonadotrophin levels.
Moreover, independent of chronological age, ovarian age-
ing affects both oocyte fecundity and quality [43] and can
negatively impact on the outcome of ART.
Factors that influence the rate of ovarian ageing
Both genetic and environmental factors influence the rate
of ovarian ageing and ovarian sensitivity to gonado-
trophins.
Genetic influences on biological ovarian age and sensitivity to 
gonadotrophins
It is well established that genetic variations may affect
ovarian response to gonadotrophins and ovarian ageing
and even premature menopause. For instance, fragile X-
associated primary ovarian insufficiency affects a propor-
tion of female carriers of a mutated version of the FMR1
gene [44]. It has been suggested that certain single nucle-
otide polymorphisms also affect sensitivity to gonado-
trophins and ovarian ageing [45].
An extreme example of the relevance of a genetic cause of
reduced ovarian gonadotrophin sensitivity to accelerated
biological ageing is provided by the FSH-receptor haplo-
insufficient knock-out mouse (FSH-R+/-); these animals
consequently have ovarian insensitivity due to a reduced
number of FSH receptors [46]. FSH-R+/- mice reach repro-
ductive maturity earlier but have smaller litter sizes than
their wild-type counterparts [47]. There is no difference in
the total number of follicles in the ovaries of 3-month-old
FSH-R+/- versus wild-type mice. However, the ovaries of
7-month-old FSH-R+/- mice contain significantly fewer
oocytes than wild-type controls, and serum gonado-
trophins are higher [47].
Additionally, it has been demonstrated that oocytes
obtained from older women may have inadequate
reserves of energy due to age-related accumulated effects
on their mitochondrial DNA [48]. Such a deficit results in
mitochondrial dysfunction and a potential increase in the
frequency of non-dysfunction, abnormalities in chroma-
tid separation. These events probably contribute to the
age-related increase in oocyte aneuploidy and the subse-
quent raised risk of having a foetus with a chromosome
abnormality [49,50]. Another study suggests that chaotic
mosaicism in human pre-implantation embryos is corre-
lated with a low mitochondrial membrane potential, and
this mechanism programs the developmental fate of
embryos [51].
The importance of genetic characteristics in determining
ovarian cycle and ovarian morphology with respect to the
FSH receptor has also been described [52]. Women with
the FSH receptor Ser680/Ser680  genotype, comprising
approximately 20% of the female population, showed a
significant increase in total menstrual cycle length and
time from luteolysis to ovulation compared with control
subjects (Asn680/Asn680 wild-type receptor). In addition,
despite being normo-ovulatory, women with the Ser680
polymorphism displayed a significantly higher serum
FSH level compared with the control population [52].
Consequently, this genotype is associated with a higher
ovarian threshold to FSH and women with the Ser680 pol-
ymorphism have been reported to have a lower ovarian
response to FSH stimulation during ART [53].
Some women undergo premature menopause whereas oth- ers conceive naturally in their late forties Figure 3
Some women undergo premature menopause 
whereas others conceive naturally in their late for-
ties. Reproduced with permission from Ferrell et al. Moni-
toring reproductive aging in a 5-year prospective study: 
aggregate and individual changes in luteinizing hormone and 
follicle-stimulating hormone with age. Menopause 2007, 
14:29-37.
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Although much research into ovarian resistance to gona-
dotrophins and ovarian ageing has focused on the gona-
dotrophin receptors, it is also important to consider the
gonadotrophins themselves and other systems. A com-
mon variant of the LH gene (Trp8Arg and Ile15Thr of the
beta subunit) encodes a protein with altered in vitro and in
vivo activity [54], which thus may be less effective at sup-
porting FSH-stimulated multi-follicular growth, resulting
in a suboptimal ovarian response to standard stimulation
regimens and in higher drug consumption [55]. An
increased prevalence of the LH gene, beta subunit variant
has been reported in Japanese patients with premature
ovarian failure [56] and in Japanese infertility patients
[57]. Therefore, women with this gene variant could ben-
efit from exogenous LH supplementation during ovarian
stimulation.
A possible link between ovarian age and the tumour sup-
pressor gene, phosphatase and tensin homologue (PTEN)
has been suggested. In a PTEN knock-out mouse model,
all primordial ovarian follicles were activated prematurely
[58]. In addition, although the low-density lipoprotein
receptor-related protein 5 (LRP5) gene is considered to be
primarily associated with bone metabolism via Wnt sig-
nalling, gene polymorphisms have been associated with a
marked variation in circulating FSH levels in normal post-
menopausal women [59].
Environmental influences on fecundity, biological ovarian age and 
sensitivity to gonadotrophins
Data from three epidemiological studies on the effect of
biological and behavioural determinants of fertility in
Bangladesh during 1975-1989 [60], 1981-1991 [61] and
1993-1994 [62] have shown that when women were strat-
ified according to age there was a progressive decrease in
fecundity rate, even among younger patients. Two studies
reported that there was a significant effect of female edu-
cation, female employment [61] and access to media
(radio) on contraceptive use and a subsequent decline in
fertility as women became more aware of family planning
methods and viewed contraception more positively [62].
Lactational infecundity was also reported as a significant
fertility-reducing factor in this population, although this
factor was judged to remain constant while the fertility-
reducing effect of contraception was predicted to increase
[60].
Environmental factors may shorten the functional
lifespan of a woman's ovaries. Diet may play a role in the
occurrence of early menopause [63]. Cigarette smoking is
one of the most common and important factors that has
been found to reduce ovarian reserve [64]. Compounds in
tobacco exert a deleterious effect on follicle maturation
[65] and enhance follicle damage and premature ovarian
failure [66]. The ovaries are extremely sensitive to aggres-
sive chemotherapy or radiotherapy regimens for the treat-
ment of cancer [67] and women receiving alkylating
agents such as cyclophosphamide and chlorambucil are at
particularly high risk of gonadal dysfunction [68].
Although the precise mechanisms involved are incom-
pletely understood, ovarian histology studies have shown
that follicle stores are depleted and ovarian atrophy occurs
after chemotherapy or radiotherapy treatment [67,69-72].
The effect of co-existing pathology on ovarian sensitivity to 
gonadotrophins
There is an association between endometriosis and infer-
tility (30-50% of patients with endometriosis are infertile)
but the visible endometriotic lesions contribute only a
small proportion of the reduced fecundity of these
women [73]. Data suggest that the adverse effects of
endometriosis are not only related to abnormalities of
reproductive anatomy but rather act to impair oocyte
development [74]. A meta-analysis of data from two ran-
domized trials showed that laparoscopic excision or abla-
tion of lesions may improve the fertility of women with
mild or moderate endometriosis [75].
There is also evidence of reduced responsiveness to gona-
dotrophins following laparoscopic ovarian cystectomy
[76], suggesting that surgical treatment of endometriosis
may further decrease a woman's ovarian reserve. Thus, it
has been suggested that ovarian surgery should be under-
taken only for the treatment of large endometriotic cysts
or to treat pain that is refractory to medical treatment or
exclude malignancy [77].
Impact of chronological versus biological age on ART 
treatment outcomes
Although ART treatments are now available for patients
experiencing fertility problems, the likelihood of success-
ful outcomes decreases with increasing female age. Poor
ovarian response to stimulation is more common in
women aged ≥35 years as the ovaries become less sensitive
to FSH with increasing age [78]. The probability of
embryo implantation and successful live birth after in vitro
fertilization (IVF) also declines progressively in women
over the age of 35 years [79,80] (Fig. 4). However, the out-
come for patients using donor eggs remains relatively con-
stant with increasing age, demonstrating that poor
outcomes in older women relate to oocyte rather than to
uterine factors [81].
Thus, biological ovarian age may be more important for
the prognosis of fertility treatment than chronological
ovarian age [43]. As a greater proportion of older patients
present for ART, it will become increasingly important to
critically assess their prognosis in order to counsel them
appropriately and optimize treatment strategies. The use
of biomarkers and genetic markers may allow estimation
of the biological ovarian age of individual patients. ThisReproductive Biology and Endocrinology 2009, 7:101 http://www.rbej.com/content/7/1/101
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information could assist greatly in informing patients and
optimizing their management.
Biological ovarian age and ovarian response
As previously described, the menopause marks the deple-
tion of follicles to below a critical threshold of approxi-
mately 1000, and the age at which menopause occurs is
highly variable [24]. Biological ovarian age, as assessed by
ovarian response to FSH during ART, can be used to pre-
dict the time to menopause (Fig. 5). A retrospective cohort
study showed that a low residual number of oocytes, as
reflected by a low number of oocytes (0-3) retrieved at
first IVF treatment, is an important predictor of the risk of
an early menopausal transition [82]. Ovarian response to
gonadotrophins may, therefore, be important for appro-
priate counselling and management of patients undergo-
ing ART.
Biological ovarian age and pregnancy rates
Biological ovarian age as assessed by FSH levels is an
important prognostic factor for IVF-related pregnancy
rates (Fig. 6). Studies have shown that elevated basal FSH
levels are associated with a poor response to ovarian stim-
ulation, which may be due to reduced oocyte numbers
and can lead to lower ART pregnancy rates [83-86].
Akande et al. studied the ability of fertilized oocytes to
implant successfully in relation to ovarian age as indicated
by basal FSH levels. The authors reported that ovarian age-
ing affects both oocyte fecundity and quality, and can
occur independently of chronological age [43].
ART management strategies for patients with biological 
ovarian ageing
Despite major advances in medical technology, there is
currently no ART treatment strategy that can fully com-
pensate for the natural decline of fertility with increasing
age [2]. For example, simply using a high dose (300 IU) of
FSH during ART will not improve pregnancy rates among
women with an expected poor response (antral follicle
count [AFC] [2-5 mm] < 5) [87]. Various adjuvant thera-
pies for improving ART outcomes in women of advanced
reproductive age have been suggested, such as the admin-
istration of exogenous LH or growth hormone (GH). Sev-
eral potentially useful biomarkers are also emerging that
can identify women with accelerated biological ovarian
ageing. Patients with biologically older ovaries may bene-
fit from a tailored approach based on individual charac-
Pregnancy and live birth rates following ART decline with  increasing age Figure 4
Pregnancy and live birth rates following ART decline 
with increasing age. Based on SART data.
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teristics to maximize the chances of the low numbers of
healthy follicles developing successfully.
Assessment of biological age using biomarkers
Although the diagnostic accuracy and clinical value of cur-
rently available tests of ovarian reserve is modest [88],
there has been much interest in the use of basal hormone
levels (serum FSH, AMH, INH B) or the AFC prior to stim-
ulation. The decreasing sensitivity of the ovaries to FSH
with age is reflected by rising basal serum FSH levels,
which provide a crude surrogate marker of biological
ovarian age when paired with the chronological age.
The AFC represents a better marker than either chronolog-
ical age or basal FSH for assessing the ovarian biological
age, and may be used to select older patients who have a
good prognosis for IVF [89]. Older patients undergoing
ovarian stimulation for IVF generally have lower AFCs
than younger patients. A high AFC gives an older patient
a better prognosis for IVF treatment outcome [90-92].
However, different genetic characteristics with respect to
the FSH receptor may mean that using AFC as a sole
assessment of IVF prognosis may be confounded in some
women. Women with the FSH receptor Ser680/Ser680 gen-
otype show a significantly greater increase in AFC during
the early follicular phase compared with the Asn680/
Asn680 (wild-type) genotype, and Ser680/Ser680 genotypes
demonstrate ovarian resistance to FSH [52].
Because of their production by immature ovarian follicles,
AMH and INH are also promising biomarkers of ovarian
ageing [93,94]. Early follicular phase serum AMH levels
correlate with the number of antral follicles [94-96] and
oocytes retrieved [97,98] and live birth after ovarian stim-
ulation [99]. AMH levels also decline progressively during
the 5 years prior to the menopause [100].
Baseline AMH levels have been used successfully to indi-
vidualize ovarian stimulation [101]. A recent study dem-
onstrated that using a mixed treatment strategy of
gonadotrophin-releasing hormone (GnRH) long agonist
or antagonist protocols (rather than simply adjusting the
FSH dose) resulted in good clinical pregnancy rates [101].
Importantly, it was shown that the use of a GnRH antago-
nist regimen for women with reduced circulating AMH
levels (1-4.9 pmol/l) was associated with a trend towards
increased clinical pregnancy rates, and reduced cycle can-
cellations and treatment burden compared with other
study populations [101].
LH supplementation
The 'two cell - two gonadotrophin' model highlighted the
role of LH in androgen production and release through-
out folliculogenesis, and founded the concept that granu-
losa and theca cells are distinct follicular compartments
regulated by FSH and LH, respectively [15,102]. This clas-
sic model has since been revised to take account of the
induction of granulosa cell LH receptor expression by FSH
during advanced stages of antral follicular development
[15,103-105]. Thus, LH regulates and integrates both
granulosa and theca cell function during late preovulatory
development.
FSH and LH cooperate to induce the local production of
growth factors, which are required for the paracrine regu-
lation of follicular maturation (although LH supersedes
FSH to sustain granulosa cell function during intermedi-
ate-late stages of folliculogenesis) [106,107]. It has been
proposed that a lack of either gonadotrophin may be
counteracted by higher levels of the other. Indeed, FSH
activity can be totally substituted by LH once granulosa
cells express adequate numbers of LH receptors
[104,108]. Conversely, increasing the dose of exogenous
FSH during controlled ovarian stimulation can overcome
GnRH-agonist mediated reduction of LH in many
women.
This hypothesis explains why a low LH concentration or
activity (below a subcritical threshold) may lead to
impaired granulosa paracrine signalling and a corre-
spondingly higher requirement for FSH. Furthermore, this
theory gave rise to a suggestion that women with ovarian
resistance to exogenous FSH, such as those with biologi-
cally older ovaries, may benefit from LH supplementa-
tion. Although some studies have failed to show an effect
of LH supplementation in older women (≥35 years
[109,110] or ≥40 years [111]), evidence of a beneficial
effect of LH supplementation is gradually accumulating.
In a prospective randomized study using a long GnRH
down-regulation protocol, significantly lower implanta-
tion and pregnancy rates were observed in women aged
≥35 years than in those aged <35 years when only recom-
binant human (r-h)FSH was used for ovarian stimulation
(P < 0.03 and P < 0.05, respectively); however, no age-
related differences were found in women who received
supplementation with r-hLH [112]. Moreover, the
implantation rate among women aged ≥35 years who
received r-hLH was significantly higher than in those who
did not (P < 0.05) [112]. Similarly, the clinical pregnancy
rate among patients aged ≥35 years at their first ART cycle
was significantly higher if they received r-hLH than if they
did not [113].
In a randomized controlled trial (using a GnRH antago-
nist), LH supplementation was associated with a signifi-
cant improvement in implantation rates in women aged
36-39 years than stimulation with only FSH (26.7% vs
18.9%;  P  = 0.03), but this effect was not observed in
younger patients [114]. Another positive effect of LH sup-Reproductive Biology and Endocrinology 2009, 7:101 http://www.rbej.com/content/7/1/101
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plementation was reported in a study of women aged >37
years at risk of a poor ovarian response (FSH > 7.6 IU/l)
who received a flexible GnRH antagonist protocol with r-
hLH supplementation, which resulted in a significantly
greater number of mature oocytes than did a standard
GnRH agonist short protocol [115].
Recent studies have attempted to define specific patient
populations that would benefit most from LH supple-
mentation. The greatest benefit of LH in ART has been
seen in women with reduced responsiveness to gonado-
trophin stimulation [116-121], which, it could be hypoth-
esized, are those with biologically older ovaries. These
early data are supported by a Cochrane systematic review
in which a significantly higher pooled estimate of ongo-
ing pregnancy was demonstrated in a sub-analysis of data
from poor responders who received r-hLH supplementa-
tion [116].
LH could improve treatment outcomes following ART
without affecting oocyte numbers, for example via benefi-
cial effects of LH on oocytes via indirect routes such as
cumulus cells [122]. Cumulus cells play a vital role in the
maturation of oocytes during folliculogenesis. The direct
action of LH may protect cumulus cells from apoptosis, so
that they can continue to support the developing oocyte
until ovulation, and ensure that the oocyte can sustain fer-
tilization and early phases of embryogenesis [122].
Given the conflicting evidence and debate, more rand-
omized-controlled trials are required to fully explore the
potential utility of LH supplementation in IVF protocols.
GH supplementation
mRNA transcripts for the GH receptor are expressed in
human oocytes and throughout pre-implantation embry-
onic development [123,124]. Indeed, human GH (hGH)
receptors are present in cumulus cells, and both immature
germinal vesicle (GV) and mature metaphase II stage
oocytes [124]. Low concentrations of hGH in follicular
fluid are associated with total fertilization failure, cleavage
failure and poor embryo morphology [125].
It is likely that GH plays a role in the final stages of human
oocyte maturation and early embryogenesis as it does for
several other mammalian species [124]. hGH stimulates
cytoplasmic maturation and may have a positive role in
increasing total cell number in the embryo and in decreas-
ing apoptosis [126], as described in bovine species [127].
In addition, GH is reported to upregulate the synthesis of
insulin-like growth factor (IGF)-I, which acts to amplify
the effects of FSH on granulosa and theca cells [128].
These observations suggested a possible role for hGH in in
vitro oocyte maturation during ART. Early studies have
confirmed that the addition of hGH to culture medium
improves  in vitro maturation of immature GV oocytes
[129,130]. Thus, the in vitro use of hGH may offer an
opportunity to rescue cycles in which a high proportion of
immature oocytes are retrieved [130].
The use of hGH in the management of female subfertility
was first reported in the early 1990s [131,132] and since
then its clinical use has been controversial. Although there
are substantial in vitro data showing the critical impor-
tance of the IGF-IGFBP family (IGF-I, IGF-II and their
binding proteins) to follicular development [133,134],
subsequent studies failed to demonstrate a therapeutic
advantage [135-141].
Interestingly, recent studies have shown more promising
results. In a randomized trial of 100 women aged >40
years, co-stimulation with hGH (8 IU daily) led to signif-
icantly higher plasma and intrafollicular oestradiol levels,
and clinical pregnancy and live birth rates, than did a
standard ovarian stimulation protocol [142]. These data
suggest that hGH may improve the potential for oocyte
development and counteract the age-related decline of
oocyte quality [142]. Kucuk et al. reported a significant
increase in the number of oocytes recovered in poor
responders receiving GH co-treatment with a GnRH ago-
nist long protocol [128]. A recent systematic review and
meta-analysis on the use of hGH in poor responders to
ovarian stimulation concluded that there is some evi-
dence to support a beneficial effect of GH on pregnancy
rates [143]. Four placebo-controlled studies of poor
responders were identified [131,136,139,144] and data
from 82 patients were pooled. The addition of GH to
ovarian stimulation protocols was shown to significantly
increase live birth rates (odds ratio 5.22, 95% confidence
interval 1.09-24.99; P = 0.04).
Conclusion
Biological ovarian age is more important than chronolog-
ical age in predicting the outcome of ART. An increasing
number of older patients are now presenting for ART
treatment, and efforts should be made to critically assess
each patient's biological ovarian age in order to counsel
them appropriately regarding prognosis, and optimize
individual treatment. When endogenous LH levels are
heavily suppressed by GnRH analogues, LH supplementa-
tion may help to optimize treatment outcomes for
women with biologically older ovaries. The potential
genetic influences on ovarian gonadotrophin sensitivity
discussed here are intriguing, and have encouraged an
approach based on systems biology to further improve
our understanding of gonadal function and ageing. Such
translational medical research could refine the use of cur-
rent therapies, producing valuable predictive models to
guide use of current treatments, and may ultimately lead
to a range of new therapies.Reproductive Biology and Endocrinology 2009, 7:101 http://www.rbej.com/content/7/1/101
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